Charles Schwab Investment Management Inc. Purchases 6,115 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)

Charles Schwab Investment Management Inc. raised its position in Akero Therapeutics, Inc. (NASDAQ:AKROFree Report) by 1.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 425,545 shares of the company’s stock after purchasing an additional 6,115 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.76% of Akero Therapeutics worth $9,936,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Headlands Technologies LLC bought a new position in Akero Therapeutics in the fourth quarter valued at about $28,000. New York State Common Retirement Fund raised its position in shares of Akero Therapeutics by 3.6% during the fourth quarter. New York State Common Retirement Fund now owns 34,545 shares of the company’s stock worth $807,000 after acquiring an additional 1,214 shares during the last quarter. abrdn plc bought a new position in shares of Akero Therapeutics during the fourth quarter worth about $1,671,000. HealthInvest Partners AB bought a new position in shares of Akero Therapeutics during the fourth quarter worth about $360,000. Finally, Strs Ohio raised its position in shares of Akero Therapeutics by 100.0% during the fourth quarter. Strs Ohio now owns 2,000 shares of the company’s stock worth $46,000 after acquiring an additional 1,000 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. UBS Group raised their price objective on Akero Therapeutics from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th. Canaccord Genuity Group decreased their target price on Akero Therapeutics from $59.00 to $56.00 and set a “buy” rating for the company in a research note on Monday, May 13th. Evercore ISI decreased their target price on Akero Therapeutics from $50.00 to $38.00 and set an “outperform” rating for the company in a research note on Wednesday, May 15th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Akero Therapeutics in a research note on Monday, May 13th. Finally, Bank of America initiated coverage on Akero Therapeutics in a research note on Monday, April 22nd. They set a “neutral” rating and a $30.00 target price for the company. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $41.13.

Get Our Latest Stock Analysis on AKRO

Akero Therapeutics Stock Down 1.9 %

Shares of NASDAQ:AKRO opened at $18.31 on Friday. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -5.72 and a beta of -0.29. The business’s 50 day moving average is $21.31 and its 200 day moving average is $21.82. The company has a quick ratio of 30.12, a current ratio of 30.12 and a debt-to-equity ratio of 0.04. Akero Therapeutics, Inc. has a 12-month low of $11.25 and a 12-month high of $58.38.

Akero Therapeutics (NASDAQ:AKROGet Free Report) last issued its earnings results on Thursday, February 29th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.17). On average, sell-side analysts forecast that Akero Therapeutics, Inc. will post -3.87 earnings per share for the current fiscal year.

Insider Buying and Selling at Akero Therapeutics

In other Akero Therapeutics news, CEO Andrew Cheng sold 75,000 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $32.87, for a total value of $2,465,250.00. Following the sale, the chief executive officer now directly owns 591,416 shares in the company, valued at $19,439,843.92. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO Andrew Cheng sold 75,000 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $32.87, for a total transaction of $2,465,250.00. Following the sale, the chief executive officer now owns 591,416 shares of the company’s stock, valued at approximately $19,439,843.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Catriona Yale sold 20,646 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $35.49, for a total value of $732,726.54. Following the sale, the insider now directly owns 78,415 shares in the company, valued at approximately $2,782,948.35. The disclosure for this sale can be found here. Insiders have sold a total of 105,646 shares of company stock worth $3,420,627 over the last ninety days. 7.94% of the stock is currently owned by company insiders.

About Akero Therapeutics

(Free Report)

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.

Featured Articles

Want to see what other hedge funds are holding AKRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akero Therapeutics, Inc. (NASDAQ:AKROFree Report).

Institutional Ownership by Quarter for Akero Therapeutics (NASDAQ:AKRO)

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.